Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Agra Ventures Ltd C.AGRA

Agra Ventures Ltd. is a Canada-based diversified company focused on the international cannabis industry. The Company is engaged in the cultivation, distribution and marketing of cannabis and cannabis-infused products around the world. It has a portfolio of licensed upstream, downstream, and product formulation assets. Its primary asset in Canada is Boundary Bay Cannabis, a cannabis greenhouse facility focused on the cultivation of high-potency cannabis. The Company's wholly owned subsidiary, Farmako GmbH (Farmako), is a distributor of medical cannabis. Farmako distributes the products in its network of German pharmacies. Its products have Farmako's branding. The products initially include high potency tetrahydrocannabinol (THC) flower and balanced THC and cannabidiol (CBD) flower. Farmako has product distribution operations in Germany and in the United Kingdom.


CSE:AGRA - Post by User

Post by EnoughBullon Dec 14, 2022 6:08pm
278 Views
Post# 35172002

Having AGRA having Organigram Wrrrr $$$

Having AGRA having Organigram Wrrrr $$$

AGRA is eligible to receive approximately 43 per cent of an additional $9,500,000 of Organigram common shares, receivable upon the EIC business achieving certain earn-out milestones, as listed below:

  • $7,000,000 to be received in common shares of Organigram upon the successful earning of $15,000,000 in net revenue during the 12 months ended Dec. 31, 2022; and
  • $2,500,000 to be received in common shares of Organigram on the generation of $7,000,000 in adjusted earnings before interest, taxes, depreciation and amortization for the 12 months ended Dec. 31, 2022.
  •  
<< Previous
Bullboard Posts
Next >>